At the 2023 Oncology Nursing Society (ONS) Bridge Conference, Dr. Lauren Ghazal, Assistant Professor in the School of Nursing at the University of Rochester Medical School and Oncology Data Advisor Editorial Board member, gave the keynote presentation entitled "Finding Your Why." Afterwards, she sat down to share further insights into the presentation, advice for nurses who are reflecting upon their "why" at different stages of their career, and how asking this question will not only help nurses to build fulfilling careers but to also strengthen nursing sustainability on a larger scale.

 

In this panel discussion, Oncology Data Advisor and MedNews Week join forces to discuss the power of holding interdisciplinary conversations in oncology and the value of bringing together individuals from diverse backgrounds, locations, career stages, and specialties to share their perspectives on oncology practice and disseminate their knowledge to others in the field.  

This interview features Oncology Data Advisor Fellows Forum member Dr. Nida Khan, a Medical Oncology and Palliative Care Fellow at The Ohio State University, and Editorial Board member Dr. Joseph Kalis, Ambulatory Oncology Pharmacy Specialist at the University of Colorado Health, in a multidisciplinary conversation for Pain Awareness Month. Dr. Khan and Dr. Kalis explain the different types of pain trajectories, particularly for patients with cancer, and the unique ways in which they approach pain management in their different specialties.  

This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  

This interview features Oncology Data Advisor Fellows Forum member Dr. Nida Khan, a Medical Oncology and Palliative Care Fellow at The Ohio State University, and Editorial Board member Dr. Joseph Kalis, Ambulatory Oncology Pharmacy Specialist at the University of Colorado Health, in a multidisciplinary conversation for Pain Awareness Month. Dr. Khan and Dr. Kalis explain the different types of pain trajectories, particularly for patients with cancer, and the unique ways in which they approach pain management in their different specialties.  

In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to prostate cancer, up-to-date diagnostic techniques, and updates in therapeutic selection and treatment.  

This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  

This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.  

This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.  

In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.  

Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  

In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.  

In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.  

Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  

In this interview, Ofer Sharon, MD, the CEO of OncoHost, explains the unique opportunities for harnessing precision medicine in oncology, the unmet needs regarding biomarker development, and the potential of utilizing a multicomponent biomarker approach for understanding the mechanisms of therapy resistance and developing novel pathways for treatment.  

Megan-Claire Chase, a patient advocate and invasive lobular breast cancer survivor, recently appeared on the "Beyond Cancer" Episode of PBS's Stories from the Stage. In this interview, Ms. Chase shares more about the experience and the important messages for patients, survivors, and clinicians that she hoped to convey in her talk and throughout her advocacy.